241 related articles for article (PubMed ID: 19401974)
1. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
2. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
[No Abstract] [Full Text] [Related]
3. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
4. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
5. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
6. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
7. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
8. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
9. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
[TBL] [Abstract][Full Text] [Related]
10. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
11. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
[No Abstract] [Full Text] [Related]
13. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
14. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib.
Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE
Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486
[No Abstract] [Full Text] [Related]
15. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
[No Abstract] [Full Text] [Related]
16. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
[No Abstract] [Full Text] [Related]
17. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
[No Abstract] [Full Text] [Related]
18. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
19. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
